Cost-effectiveness as a price control

Health Affairs

Volumn 26, Issue 3, 2007, Pages 696-703

  Jena, Anupam B ^a   Philipson, Tomas ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Harris School for Graduate Public Policy Studies

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; MASS COMMUNICATION; METHODOLOGY; MOTIVATION; RESEARCH; REVIEW; SOCIAL PSYCHOLOGY; UNITED STATES;

COMMERCE; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DIFFUSION OF INNOVATION; HUMANS; MOTIVATION; RESEARCH; SOCIAL VALUES; UNITED STATES;

EID: 34248513278     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.26.3.696     Document Type: Review

References (14)

1. J.P. Newhouse, "Medical Care Costs: How Much Welfare Loss?" Journal of Economic Perspectives 6, no. 3 (1992): 3-21.
2. B. George, A. Harris, and A. Mitchell, "Cost-Effectiveness Analysis and the Consistency of Decision Making: Evidence from Pharmaceutical Reimbursement in Australia (1991 to 1996)," PharmacoEconomics 19, no. 11 (2001): 1103-1109.
3. M. Drummond et al., Methods for the Economic Evaluation of Health Care Programmes (New York: Oxford University Press, 1997);
4. A.M. Garber and C.E. Phelps, "Economic Foundations of Cost-Effectiveness Analysis," Journal of Health Economics 16, no. 1 (1997): 1-31;
5. and M. Gold et al., Cost-Effectiveness in Health and Medicine (New York: Oxford University Press, 1996).
6. T. Philipson and A. Jena, "Surplus Appropriation from R&D and Health Care Technology Assessment Procedures," NBER Working Paper no. 12106 (Cambridge, Mass.: National Bureau of Economic Research, 2006).
7. U.S. Department of Commerce, Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation (Washington: DOC, 2004).
8. See, for example, A.M. Garber, C.T. Jones, and P. Romer, "Insurance and Incentives for Medical Innovation," Forum for Health Economics and Policy, Forum: Biomedical Research and the Economy: Article 4 (2006);
9. and T. Philipson, S. Mechoulan, and A. Jena, "IP and External Consumption Effects: Generalizations from Health Care Markets," NBER Working Paper no. 11930 (Washington: NBER, 2006).
10. See, for example, W. Nordhaus, "The Health of Nations: The Contribution of Improved Health to Living Standards," in Measuring the Gains from Medical Research: An Economic Approach, ed. K. Murphy and R. Topel (Chicago: University of Chicago Press, 2003).
11. M. Duggan and W. Evans, "The Impact of HIV Antiviral Treatments: Evidence for California's Medicaid Population" (Working paper, University of Maryland, 2005).
12. T. Philipson and A. Jena, "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs," Forum for Health Economics and Policy, Forum: Biomedical Research and the Economy: Article 3 (2005).
13. D. Cutler and E. Richardson, "The Value of Health: 1970-1990," American Economic Review 88, no. 2 (1998): 97-100.
14. F. Lichtenberg, "The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditure: An Assessment Based on Aggregate U.S. Time-Series Data" (Working paper, Columbia Business School, 2005).